Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
September 25 2023 - 4:05PM
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced it will
host a conference call and webcast on Tuesday, September 26, 2023
at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from
the INTEGRIS-PSC Phase 2a trial. Members of Pliant’s management
will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry
Horner Chair in Autoimmune Liver Disease at the University of
Toronto and a principal investigator in the INTEGRIS-PSC trial.
The conference call will be simultaneously webcast online and
will be accessible from the Events & Presentation section of
Pliant’s website. The live audio of the conference call can be
accessed by telephone by registering in advance at the following
link: Pliant Therapeutics INTEGRIS-PSC Conference Call. Upon
registration, all telephone participants will receive the dial-in
number along and a unique passcode to access the call. An archived
replay of the webcast will be available on Pliant’s website for 60
days following completion of the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical
company focused on discovering and developing novel therapies for
the treatment of fibrosis. Pliant's lead product candidate,
bexotegrast (PLN-74809), is an oral, small molecule, dual selective
inhibitor of αvß6 and αvß1 integrins that is in development in the
lead indications for the treatment of idiopathic pulmonary
fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Bexotegrast has received Fast Track Designation and Orphan Drug
Designation from the U.S. Food and Drug Administration (FDA) in IPF
and PSC and Orphan Drug Designation from the European Medicines
Agency in IPF and PSC. Pliant has initiated BEACON-IPF, a Phase 2b
trial of bexotegrast in IPF. Pliant has also developed PLN-1474, a
small molecule, selective inhibitor of αvß1 integrin for the
treatment of nonalcoholic steatohepatitis, or NASH with liver
fibrosis. Pliant has initiated a Phase 1 study for its third
clinical program, PLN-101095, a small molecule, dual-selective
inhibitor of αvß8 and αvß1 integrins, that is being developed for
the treatment of solid tumors. In addition to clinical stage
programs, Pliant currently has a preclinical program targeting
muscular dystrophies. For additional information, please
visit: www.PliantRx.com. Follow us on social media
Twitter, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and
Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Apr 2024 to May 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From May 2023 to May 2024